{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T03:40:05Z","timestamp":1750563605115,"version":"3.41.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,21]]},"DOI":"10.7759\/cureus.86507","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T03:22:02Z","timestamp":1750562522000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable Response to Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma With Extensive Gluteal and Sacral Bone Infiltration: A 12-Month Case"],"prefix":"10.7759","author":[{"given":"Ivan","family":"Bivolarski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from two open-label, phase 2, single-arm trials","volume":"21","author":"Migden MR","year":"2020","unstructured":"Migden MR, Rischin D, Schmults CD, et al.. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from two open-label, phase 2, single-arm trials. Lancet Oncol. 2020, 21:294-305. 10.1016\/S1470-2045(19)30728-4","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden MR","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, et al.. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018, 379:341-51. 10.1056\/NEJMoa1805131","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment","volume":"128","author":"Stratigos AJ","year":"2020","unstructured":"Stratigos AJ, Garbe C, Dessinioti C, et al.. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment. Eur J Cancer. 2020, 128:60-82. 10.1016\/j.ejca.2020.01.008","journal-title":"Eur J Cancer"},{"key":"ref4","unstructured":"Squamous cell skin cancer. (2025). Accessed. June 21, 2025: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1465."},{"key":"ref5","unstructured":"FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. (2019). Accessed. June 21, 2025: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cu...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061581","article-title":"Multidisciplinary management of cutaneous squamous cell carcinoma of the scalp: an algorithm for reconstruction and treatment","volume":"13","author":"Rodio M","year":"2024","unstructured":"Rodio M, Tettamanzi M, Trignano E, et al.. Multidisciplinary management of cutaneous squamous cell carcinoma of the scalp: an algorithm for reconstruction and treatment. J Clin Med. 2024, 13:1581. 10.3390\/jcm13061581","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2018.3650","article-title":"Association of adjuvant radiation therapy with survival in patients with advanced cutaneous squamous cell carcinoma of the head and neck","volume":"145","author":"Harris BN","year":"2019","unstructured":"Harris BN, Pipkorn P, Nguyen KNB, et al.. Association of adjuvant radiation therapy with survival in patients with advanced cutaneous squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg. 2019, 145:153-8. 10.1001\/jamaoto.2018.3650","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-46227-7_6","article-title":"Epidemiology of skin cancer: update 2019","author":"Leiter U","year":"2020","unstructured":"Leiter U, Keim U, Garbe C. Epidemiology of skin cancer: update 2019. Sunlight, Vitamin D and Skin Cancer. Advances in Experimental Medicine and Biology. Reichrath J (ed): Springer, Cham, Switzerland; 2020. 10.1007\/978-3-030-46227-7_6"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0210","article-title":"Treatment of unresectable and metastatic cutaneous squamous cell carcinoma","volume":"15","author":"Cranmer LD","year":"2010","unstructured":"Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010, 15:1320-8. 10.1634\/theoncologist.2009-0210","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3498","article-title":"Update of the management of cutaneous squamous-cell carcinoma","volume":"100","author":"Maubec E","year":"2020","unstructured":"Maubec E. Update of the management of cutaneous squamous-cell carcinoma. Acta Derm Venereol. 2020, 100:adv00143. 10.2340\/00015555-3498","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S445910","article-title":"Real-world treatment patterns and outcomes of cemiplimab in patients with advanced cutaneous squamous cell carcinoma treated in US oncology practices","volume":"16","author":"Ge W","year":"2024","unstructured":"Ge W, Wu N, Chen CI, et al.. Real-world treatment patterns and outcomes of cemiplimab in patients with advanced cutaneous squamous cell carcinoma treated in US oncology practices. Cancer Manag Res. 2024, 16:841-54. 10.2147\/CMAR.S445910","journal-title":"Cancer Manag Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1876567","article-title":"Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel","volume":"21","author":"Lebas E","year":"2021","unstructured":"Lebas E, Marchal N, Rorive A, Nikkels AF. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Expert Rev Anticancer Ther. 2021, 21:355-63. 10.1080\/14737140.2021.1876567","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01044-8","article-title":"Real\u2011world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)","volume":"123","author":"Hanna GJ","year":"2020","unstructured":"Hanna GJ, Ruiz ES, LeBoeuf NR, et al.. Real\u2011world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer. 2020, 123:1535-42. 10.1038\/s41416-020-01044-8","journal-title":"Br J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030606","article-title":"Epidemiology of keratinocyte skin cancer with a focus on cutaneous squamous cell carcinoma","volume":"16","author":"Nanz L","year":"2024","unstructured":"Nanz L, Keim U, Katalinic A, Meyer T, Garbe C, Leiter U. Epidemiology of keratinocyte skin cancer with a focus on cutaneous squamous cell carcinoma. Cancers (Basel). 2024, 16:606. 10.3390\/cancers16030606","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61196-X","article-title":"Non-melanoma skin cancer","volume":"375","author":"Madan V","year":"2010","unstructured":"Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010, 375:673-85. 10.1016\/S0140-6736(09)61196-X","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408667","article-title":"Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (real world evidence of advanced CSCC treatment with cemiplimab)","volume":"15","author":"Challapalli A","year":"2024","unstructured":"Challapalli A, Stewart G, Shaw H, Davies PJ, Lopez-Baez JC, Ottley EC, Kelly S. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (real world evidence of advanced CSCC treatment with cemiplimab). Front Immunol. 2024, 15:1408667. 10.3389\/fimmu.2024.1408667","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01302-2","article-title":"Cemiplimab: a review in advanced cutaneous squamous cell carcinoma","volume":"80","author":"Lee A","year":"2020","unstructured":"Lee A, Duggan S, Deeks ED. Cemiplimab: a review in advanced cutaneous squamous cell carcinoma. Drugs. 2020, 80:813-9. 10.1007\/s40265-020-01302-2","journal-title":"Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0008-4","article-title":"Clocking in to immunity: circadian regulation of the immune system","volume":"18","author":"Scheiermann C","year":"2018","unstructured":"Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity: circadian regulation of the immune system. Nat Rev Immunol. 2018, 18:423-37. 10.1038\/s41577-018-0008-4","journal-title":"Nat Rev Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.03.004","article-title":"Dosing-time makes the poison: circadian regulation and pharmacotherapy","volume":"22","author":"Dallmann R","year":"2016","unstructured":"Dallmann R, Okyar A, L\u00e9vi F. Dosing-time makes the poison: circadian regulation and pharmacotherapy. Trends Mol Med. 2016, 22:430-45. 10.1016\/j.molmed.2016.03.004","journal-title":"Trends Mol Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/381069-durable-response-to-cemiplimab-in-advanced-cutaneous-squamous-cell-carcinoma-with-extensive-gluteal-and-sacral-bone-infiltration-a-12-month-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T03:22:04Z","timestamp":1750562524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/381069-durable-response-to-cemiplimab-in-advanced-cutaneous-squamous-cell-carcinoma-with-extensive-gluteal-and-sacral-bone-infiltration-a-12-month-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.86507","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,21]]}}}